29.00

4.89% -1.49

Viking Therapeutics Inc (VKTX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt VKTX? Forum Prognose

Schlusskurs vom Vortag:

$30.49

Offen:

$30.72

24-Stunden-Volumen:

2.93M

Relative Volume:

0.93

Marktkapitalisierung:

$3.35B

Einnahmen:

Nettoeinkommen (Verlust:

$-237.39M

KGV:

-13.69

EPS:

-2.1183

Netto-Cashflow:

$-224.58M

1W Leistung:

+1.97%

1M Leistung:

-5.51%

6M Leistung:

-29.73%

1J Leistung:

-1.69%

1-Tages-Spanne:

$28.75

$31.00

1-Wochen-Bereich:

$27.16

$34.38

52-Wochen-Spanne:

$18.92

$43.15

Viking Therapeutics Inc Stock (VKTX) Company Profile

Firmenname

Viking Therapeutics Inc

Sektor

Healthcare (1111)

Branche

Biotechnology (622)

Telefon

858-704-4660

Adresse

9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA

Mitarbeiter

Twitter

@viking_vktx

Nächster Verdiensttermin

2025-10-22

Neueste SEC-Einreichungen

VKTX's Discussions on Twitter

Compare VKTX vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VKTX Viking Therapeutics Inc	29.00	3.52B	0	-237.39M	-224.58M	-2.1183
VRTX Vertex Pharmaceuticals Inc	491.47	117.98B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	803.17	82.85B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	821.96	51.58B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	314.40	40.75B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.07	38.33B	4.98B	69.60M	525.67M	0.5198

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-10-29	Eingeleitet	Canaccord Genuity	Buy
2025-04-29	Eingeleitet	Cantor Fitzgerald	Overweight
2025-04-08	Eingeleitet	Goldman	Neutral
2025-02-13	Eingeleitet	Scotiabank	Sector Outperform
2025-02-07	Eingeleitet	Citigroup	Neutral
2024-12-02	Eingeleitet	Piper Sandler	Overweight
2024-11-22	Eingeleitet	B. Riley Securities	Buy
2024-11-04	Bestätigt	H.C. Wainwright	Buy
2024-09-11	Eingeleitet	JP Morgan	Overweight
2024-06-27	Eingeleitet	Morgan Stanley	Overweight
2024-05-16	Hochstufung	Raymond James	Outperform → Strong Buy
2024-03-26	Bestätigt	Oppenheimer	Outperform
2024-03-07	Eingeleitet	Jefferies	Buy
2024-02-28	Bestätigt	Oppenheimer	Outperform
2023-05-31	Fortgesetzt	ROTH MKM	Buy
2023-03-28	Bestätigt	Maxim Group	Buy
2023-03-17	Eingeleitet	Stifel	Buy
2021-07-29	Fortgesetzt	BTIG Research	Buy
2021-05-25	Herabstufung	Raymond James	Strong Buy → Outperform
2020-06-05	Eingeleitet	BMO Capital Markets	Outperform
2020-05-05	Eingeleitet	Chardan Capital Markets	Buy
2020-05-01	Eingeleitet	BTIG Research	Buy
2019-07-16	Eingeleitet	Oppenheimer	Outperform
2019-06-25	Eingeleitet	Stifel	Buy
2019-03-29	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-03-14	Bestätigt	Maxim Group	Buy
2019-02-22	Eingeleitet	SVB Leerink	Mkt Perform
2018-12-12	Eingeleitet	B. Riley FBR	Buy
2018-11-19	Hochstufung	Raymond James	Outperform → Strong Buy
2018-09-18	Bestätigt	H.C. Wainwright	Buy
2018-09-18	Bestätigt	Maxim Group	Buy
2018-09-18	Bestätigt	Raymond James	Outperform
2018-07-20	Eingeleitet	SunTrust	Buy
2018-06-28	Eingeleitet	Raymond James	Outperform
2018-06-01	Bestätigt	Laidlaw	Buy
2018-05-31	Bestätigt	Maxim Group	Buy
2018-03-26	Fortgesetzt	H.C. Wainwright	Buy
2017-11-28	Bestätigt	Maxim Group	Buy
2017-11-21	Eingeleitet	ROTH Capital	Buy

Alle ansehen

Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten

05:03 AM

Can Viking Therapeutics Inc. maintain its current growth rateFed Meeting & Short-Term Swing Trade Alerts - mfd.ru

05:03 AM

Feb 13, 2026

Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market - Benzinga

Feb 13, 2026

Viking Therapeutics (VKTX) Is Up 16.0% After Fast-Tracking VK2735 Into Phase III Trials – Has The Bull Case Changed? - Yahoo Finance

Feb 13, 2026

Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch Potential - Seeking Alpha

Feb 13, 2026

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth - 富途牛牛

Feb 13, 2026

Viking Therapeutics Advances VK2735 Toward Phase 3 After FDA Feedback - AD HOC NEWS

Feb 13, 2026

What is HC Wainwright's Forecast for VKTX Q4 Earnings? - MarketBeat

Feb 13, 2026

Is Viking Therapeutics (VKTX) Pricing Reflecting Recent Drug Development Progress? - simplywall.st

Feb 13, 2026

Viking Therapeutics' VK2735 Sees Strong Demand Amid Novo Nordisk Launch - Intellectia AI

Feb 13, 2026

Feb 12, 2026

VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits

Feb 12, 2026

Pipeline Momentum Boosts Viking Therapeutics as Phase 3 Timeline Accelerates - AD HOC NEWS

Feb 12, 2026

Viking Therapeutics (VKTX) Valuation Check After Q4 2025 Earnings And Obesity Pipeline Progress - Yahoo Finance

Feb 12, 2026

Viking Therapeutics stock rating reiterated at Buy by Laidlaw - Investing.com Nigeria

Feb 12, 2026

Viking to push oral GLP-1/GIP drug into phase III obesity trial - BioWorld MedTech

Feb 12, 2026

Viking Therapeutics Stock Soars: What's Driving The Momentum? - Benzinga

Feb 12, 2026

Stock Movers: Equinix, Crocs, Viking Therapeutics - Bloomberg.com

Feb 12, 2026

Viking Therapeutics stock price target lowered to $118 by Raymond James By Investing.com - Investing.com Canada

Feb 12, 2026

Viking Therapeutics stock rating reiterated at Buy by Laidlaw By Investing.com - Investing.com South Africa

Feb 12, 2026

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - marketscreener.com

Feb 12, 2026

Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Cuts Target Price to $99 - 富途牛牛

Feb 12, 2026

Viking Therapeutics (VKTX) Shares Rise on Promising Obesity Drug Updates - GuruFocus

Feb 12, 2026

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 12, 2026

Viking Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 12, 2026

VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates - Yahoo Finance

Feb 12, 2026

Viking Therapeutics stock price target lowered to $118 by Raymond James - Investing.com

Feb 12, 2026

Viking Therapeutics rises after Q4 updates (VKTX:NASDAQ) - Seeking Alpha

Feb 12, 2026

Viking Therapeutics Advances Oral Obesity Drug Toward Final Clinical Trials - AD HOC NEWS

Feb 12, 2026

Morgan Stanley Trims Price Target on Viking Therapeutics to $99 From $102, Keeps Overweight Rating - marketscreener.com

Feb 12, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Feb 12, 2026

Viking Therapeutics stock soars on plans for Phase 3 obesity drug trial - Investing.com

Feb 12, 2026

Viking Therapeutics stock (VKTX) slips premarket as Phase 3 obesity pill timeline comes into focus - Bez Kabli

Feb 12, 2026